Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Intraindividual Comparison of 18F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer

Felix Dietlein, Carsten Kobe, Melanie Hohberg, Boris D. Zlatopolskiy, Philipp Krapf, Heike Endepols, Philipp Täger, Jochen Hammes, Axel Heidenreich, Thorsten Persigehl, Bernd Neumaier, Alexander Drzezga and Markus Dietlein
Journal of Nuclear Medicine May 2020, 61 (5) 729-734; DOI: https://doi.org/10.2967/jnumed.119.234898
Felix Dietlein
1Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
2Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carsten Kobe
1Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie Hohberg
1Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Boris D. Zlatopolskiy
3Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Krapf
4Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH, Jülich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heike Endepols
1Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
3Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philipp Täger
1Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jochen Hammes
1Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Axel Heidenreich
5Department of Urology, University Hospital of Cologne, Cologne, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thorsten Persigehl
6Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernd Neumaier
3Institute of Radiochemistry and Experimental Molecular Imaging, University Hospital of Cologne, Cologne, Germany
4Institute of Neuroscience and Medicine, INM-5: Nuclear Chemistry, Forschungszentrum Jülich GmbH, Jülich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Drzezga
1Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Dietlein
1Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIGURE 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 1.

    18F-JK-PSMA-7 PET/low-dose CT (A and C) and 18F-PSMA-1007 PET/low-dose CT (B and D) images in patient 21, with biochemical recurrence. Histologically confirmed PSMA-positive lesion in right seminal vesicle is shown in Supplemental Figure 1. Osteomedullary spots with 18F-PSMA-1007 in left os ilium (red arrows in B and D), in right os ilium (blue arrow in B), and in left femur (orange arrow in B) did not have any correlate on MRI scan (E and F). Salvage prostatectomy produced excellent PSA response. DWIBS = diffusion weighted whole body imaging with background body signal suppression; mDIXON FS = multiple-echo Dixon fat suppression.

  • FIGURE 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 2.

    18F-DCFPyL PET/low-dose CT (A and C) and 18F-PSMA-1007 PET/low-dose CT (B and D) images in patient 13, with biochemical recurrence. PSMA-positive intraprostatic lesions in left and right lobes of prostate are visible with both 18F-DCFPyL and 18F-PSMA-1007 (green arrows). Osteomedullary spots in thoracic spine (T3, red arrows) did not have any correlate on MRI scan (E and F). Hemangioma in C3 was PSMA-negative (blue arrow). T1w = T1-weighted.

  • FIGURE 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIGURE 3.

    18F-JK-PSMA-7 PET/low-dose CT (A, C, and E) and 18F-PSMA-1007 PET/low-dose CT (B, D, and F) images in patient 27, with biochemical recurrence. Maximum-intensity projections with 18F-JK-PSMA-7 and 18F-PSMA-1007 show 2 PSMA-positive right iliac lymph nodes and PSMA-positive relapse below bladder. Additionally, 18F-PSMA-1007 PET scan in B shows further relapse at junction between bladder and urethra. Osteomedullary spots in cervical spine (C3, dashed red arrows in B and D) and thoracic spine (T5, solid red arrows in B and F) did not have any correlate on MRI scan (G and H).

Tables

  • Figures
  • Additional Files
    • View popup
    TABLE 1

    Contingency Table of PSMA-RADS Results for Lesions Confirmed as True-Positive for Locoregional Relapse

    PET-2
    PET-1PSMA-RADSRADS 1/2RADS 3RADS 4/5
    Reader 1RADS 1/2003
    RADS 3069
    RADS 4/5009
    Reader 2RADS 1/2015
    RADS 3042
    RADS 4/50015

Additional Files

  • Figures
  • Tables
  • Supplemental Data

    Files in this Data Supplement:

    • Supplemental Data
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (5)
Journal of Nuclear Medicine
Vol. 61, Issue 5
May 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Intraindividual Comparison of 18F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Intraindividual Comparison of 18F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer
Felix Dietlein, Carsten Kobe, Melanie Hohberg, Boris D. Zlatopolskiy, Philipp Krapf, Heike Endepols, Philipp Täger, Jochen Hammes, Axel Heidenreich, Thorsten Persigehl, Bernd Neumaier, Alexander Drzezga, Markus Dietlein
Journal of Nuclear Medicine May 2020, 61 (5) 729-734; DOI: 10.2967/jnumed.119.234898

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Intraindividual Comparison of 18F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer
Felix Dietlein, Carsten Kobe, Melanie Hohberg, Boris D. Zlatopolskiy, Philipp Krapf, Heike Endepols, Philipp Täger, Jochen Hammes, Axel Heidenreich, Thorsten Persigehl, Bernd Neumaier, Alexander Drzezga, Markus Dietlein
Journal of Nuclear Medicine May 2020, 61 (5) 729-734; DOI: 10.2967/jnumed.119.234898
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Diagnostic Efficacy of Various Imaging Modalities Across Different Stages of Prostate Cancer: A Network Meta-Analysis of Diagnostic Studies
  • Unspecific 18F-PSMA-1007 Bone Uptake Evaluated Through PSMA-11 PET, Bone Scanning, and MRI Triple Validation in Patients with Biochemical Recurrence of Prostate Cancer
  • An 89Zr-Labeled PSMA Tracer for PET/CT Imaging of Prostate Cancer Patients
  • Matched-Pair Comparison of 18F-DCFPyL PET/CT and 18F-PSMA-1007 PET/CT in 240 Prostate Cancer Patients: Interreader Agreement and Lesion Detection Rate of Suspected Lesions
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
  • 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Show more Theranostics

Clinical

  • Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
  • SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
  • Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?
Show more Clinical

Similar Articles

Keywords

  • prostate cancer
  • PET
  • PSMA tracer
  • 18F-PSMA-1007
  • 68Ga-PSMA-11
  • 18F-DCFPyL
  • 18F-JK-PSMA-7
SNMMI

© 2025 SNMMI

Powered by HighWire